Printer Friendly

THOMAS P. STOSSEL, M.D., NAMED CHAIRMAN OF PROTEIN ENGINEERING CORP.'S MEDICAL ADVISORY GROUP

 THOMAS P. STOSSEL, M.D., NAMED CHAIRMAN
 OF PROTEIN ENGINEERING CORP.'S MEDICAL ADVISORY GROUP
 CAMBRIDGE, Mass., July 13 /PRNewswire/ -- Protein Engineering Corporation (PEC) today announced that Thomas P. Stossel, MD, has been named chairman of the company's Medical Advisory Group. Dr. Stossel is the director, Division of Experimental Medicine, and physician, Hematology/Oncology Division, at Brigham & Women's Hospital of Boston. He is recognized for his research in how individual cells move in the human body to control form and defend against foreign invaders.
 "Tom Stossel brings to Protein Engineering medical expertise that will be valuable as we choose additional disease targets and develop new protein-based therapies," commented John H. Freeman, president of Protein Engineering Corp. "We are please that he has accepted the position, and we look forward to his many contributions as the company grows and advances products to the clinical stage of development."
 In addition to his positions at Brigham & Women's Hospital, Dr. Stossel is the American Cancer Society professor of medicine at Harvard Medical School. He has also served as a fellow in hematology/oncology at Children's Hospital Medical Center, and as chief of hematology/oncology at Massachusetts General Hospital. In 1983, he was awarded the Damashek Prize of the American Society of Hematology for contributions to blood research. He received his B.A. from Princeton University in 1963 and his M.D. from Harvard Medical School in 1967.
 Protein Engineering Corp.'s core technology allows the company to generate novel proteins for specific molecular targets. The company has engineered an elastase inhibitor now in preclinical development for the treatment of certain respiratory disorders such as emphysema, cystic fibrosis and bronchitis. PEC was recently issued a U.S. patent covering methods to generate and select novel proteins having binding activity for specific DNA sequence targets. PEC is using this patented technology initially to engineer proteins to block replication of viruses, which may lead to the discovery of new treatments for viral diseases. The technology may also be used to produce proteins that block the activity of harmful genes, including cancer-causing oncogenes.
 Protein Engineering Corporation was founded in 1987 to develop powerful, proprietary technology to engineer patentable proteins for use as pharmaceuticals. Company headquarters are located in Cambridge.
 -0- 7/13/92
 /CONTACT: John H. Freeman, Protein Engineering Corp., 617-868-0868, or Lynne H. Brum, Feinstein Partners, 617-577-8110, for Protein Engineering Corp./ CO: Protein Engineering Corporation ST: Massachusetts IN: MTC SU: PER


TM -- NE004 -- 8544 07/13/92 10:19 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 13, 1992
Words:413
Previous Article:FORD ANNOUNCES EXECUTIVE APPOINTMENTS
Next Article:JOB SEMINARS AT LIBERTY BANK
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters